AML   

Does your answer change based on clinical or molecular risk factors, and if so how? Does your answer change if MRD status after induction is unknown?

Is there any data on combining the two?

Is there a role for non-myeloablative regimens?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

NGS results are pending

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

If not, what instructions do you give to patients regarding checking temperature at home/return precautions?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Would you consider “bridging” therapy with something like an HMA?

Does acute leukemia sub-type affect your decision? 

Can it be added after 2 or 3 cycles of HMA?